Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 2000 Oct 26;83(10):1338–1343. doi: 10.1054/bjoc.2000.1446

Autoimmunity against p53 predicts invasive cancer with poor survival in patients with an ovarian mass

F D Vogl 1,4, M Frey 2, R Kreienberg 1, I B Runnebaum 3
PMCID: PMC2408792  PMID: 11044359

Abstract

Serum autoantibodies against the p53 protein (p53 AAb) were analysed with a newly developed enzyme-linked immunosorbent assay (ELISA) based on highly purified and renatured p53. In a hospital-based cohort study, preoperative sera from 113 patients with ovarian cancer, 15 patients with borderline tumours and 117 patients with benign tumours of the ovaries were studied. The prevalence of p53 AAb in patients with invasive cancer was 19% (21/113). No p53 AAb were found in patients with borderline lesions or benign tumours. The ELISA had a specificity for malignancy of 99% (1 of 117; false-positive from a patient with severe diabetes mellitus) and a likelihood ratio (LR+) for a positive test result of 21.7 (elevated CA125 and malignancy: LR+ 3.7). p53 AAb were only detectable in patients with immunohistochemical staining of nuclear p53 in the tumour (P= 0.006). Presence of p53 AAb positively correlated with tumour stage (P= 0.034) and grade (P= 0.009). Kaplan–Meier analysis showed both a shortened overall survival (P= 0.0016, log-rank) and relapse-free survival (P= 0.055) for p53 AAb-positive patients (median follow-up 22 months). High titres related to even worse prognosis. p53 AAb independently related to poor survival adjusting for stage (P= 0.026), grade (P= 0.029) and residual disease after surgery (P= 0.005). Preoperative findings of adnexal mass with serum p53 AAb are strongly suggestive of an aggressive invasive ovarian cancer. © 2000 Cancer Research Campaign

Keywords: p53, cohort study, adjusted analysis, prognosis, ovarian cancer

Full Text

The Full Text of this article is available as a PDF (101.3 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Angelopoulou K., Diamandis E. P., Sutherland D. J., Kellen J. A., Bunting P. S. Prevalence of serum antibodies against the p53 tumor suppressor gene protein in various cancers. Int J Cancer. 1994 Aug 15;58(4):480–487. doi: 10.1002/ijc.2910580404. [DOI] [PubMed] [Google Scholar]
  2. Angelopoulou K., Rosen B., Stratis M., Yu H., Solomou M., Diamandis E. P. Circulating antibodies against p53 protein in patients with ovarian carcinoma. Correlation with clinicopathologic features and survival. Cancer. 1996 Nov 15;78(10):2146–2152. [PubMed] [Google Scholar]
  3. Angelopoulou K., Stratis M., Diamandis E. P. Humoral immune response against p53 protein in patients with colorectal carcinoma. Int J Cancer. 1997 Jan 6;70(1):46–51. doi: 10.1002/(sici)1097-0215(19970106)70:1<46::aid-ijc7>3.0.co;2-6. [DOI] [PubMed] [Google Scholar]
  4. Caron de Fromentel C., May-Levin F., Mouriesse H., Lemerle J., Chandrasekaran K., May P. Presence of circulating antibodies against cellular protein p53 in a notable proportion of children with B-cell lymphoma. Int J Cancer. 1987 Feb 15;39(2):185–189. doi: 10.1002/ijc.2910390211. [DOI] [PubMed] [Google Scholar]
  5. Crawford L. V., Pim D. C., Bulbrook R. D. Detection of antibodies against the cellular protein p53 in sera from patients with breast cancer. Int J Cancer. 1982 Oct 15;30(4):403–408. doi: 10.1002/ijc.2910300404. [DOI] [PubMed] [Google Scholar]
  6. DePriest P. D., Gallion H. H., Pavlik E. J., Kryscio R. J., van Nagell J. R., Jr Transvaginal sonography as a screening method for the detection of early ovarian cancer. Gynecol Oncol. 1997 Jun;65(3):408–414. doi: 10.1006/gyno.1997.4705. [DOI] [PubMed] [Google Scholar]
  7. Dottino P. R., Levine D. A., Ripley D. L., Cohen C. J. Laparoscopic management of adnexal masses in premenopausal and postmenopausal women. Obstet Gynecol. 1999 Feb;93(2):223–228. doi: 10.1016/s0029-7844(98)00425-6. [DOI] [PubMed] [Google Scholar]
  8. Eltabbakh G. H., Belinson J. L., Kennedy A. W., Biscotti C. V., Casey G., Tubbs R. R., Blumenson L. E. p53 overexpression is not an independent prognostic factor for patients with primary ovarian epithelial cancer. Cancer. 1997 Sep 1;80(5):892–898. [PubMed] [Google Scholar]
  9. Gadducci A., Ferdeghini M., Buttitta F., Cosio S., Fanucchi A., Annicchiarico C., Gagetti O., Bevilacqua G., Genazzani A. R. Assessment of the prognostic relevance of serum anti-p53 antibodies in epithelial ovarian cancer. Gynecol Oncol. 1999 Jan;72(1):76–81. doi: 10.1006/gyno.1998.5101. [DOI] [PubMed] [Google Scholar]
  10. Gadducci A., Ferdeghini M., Buttitta F., Cosio S., Fanucchi A., Annicchiarico C., Genazzani A. R. Serum anti-p53 antibodies in the follow-up of patients with advanced ovarian carcinoma. Anticancer Res. 1998 Sep-Oct;18(5B):3763–3765. [PubMed] [Google Scholar]
  11. Gadducci A., Ferdeghini M., Buttitta F., Fanucchi A., Annicchiarico C., Prontera C., Bevilacqua G., Genazzani A. R. Preoperative serum antibodies against the p53 protein in patients with ovarian and endometrial cancer. Anticancer Res. 1996 Nov-Dec;16(6B):3519–3523. [PubMed] [Google Scholar]
  12. Green J. A., Robertson L. J., Campbell I. R., Jenkins J. Expression of the p53 gene and presence of serum autoantibodies in ovarian cancer: correlation with differentiation. Cancer Detect Prev. 1995;19(2):151–155. [PubMed] [Google Scholar]
  13. Harris C. C., Hollstein M. Clinical implications of the p53 tumor-suppressor gene. N Engl J Med. 1993 Oct 28;329(18):1318–1327. doi: 10.1056/NEJM199310283291807. [DOI] [PubMed] [Google Scholar]
  14. Hollstein M., Sidransky D., Vogelstein B., Harris C. C. p53 mutations in human cancers. Science. 1991 Jul 5;253(5015):49–53. doi: 10.1126/science.1905840. [DOI] [PubMed] [Google Scholar]
  15. Houbiers J. G., van der Burg S. H., van de Watering L. M., Tollenaar R. A., Brand A., van de Velde C. J., Melief C. J. Antibodies against p53 are associated with poor prognosis of colorectal cancer. Br J Cancer. 1995 Sep;72(3):637–641. doi: 10.1038/bjc.1995.386. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Lai C. L., Tsai C. M., Tsai T. T., Kuo B. I., Chang K. T., Fu H. T., Perng R. P., Chen J. Y. Presence of serum anti-p53 antibodies is associated with pleural effusion and poor prognosis in lung cancer patients. Clin Cancer Res. 1998 Dec;4(12):3025–3030. [PubMed] [Google Scholar]
  17. Lane D. P. Cancer. p53, guardian of the genome. Nature. 1992 Jul 2;358(6381):15–16. doi: 10.1038/358015a0. [DOI] [PubMed] [Google Scholar]
  18. Legros Y., Lacabanne V., d'Agay M. F., Larsen C. J., Pla M., Soussi T. Production of human p53 specific monoclonal antibodies and their use in immunohistochemical studies of tumor cells. Bull Cancer. 1993 Feb;80(2):102–110. [PubMed] [Google Scholar]
  19. Legros Y., Lafon C., Soussi T. Linear antigenic sites defined by the B-cell response to human p53 are localized predominantly in the amino and carboxy-termini of the protein. Oncogene. 1994 Jul;9(7):2071–2076. [PubMed] [Google Scholar]
  20. Lubin R., Schlichtholz B., Bengoufa D., Zalcman G., Trédaniel J., Hirsch A., Caron de Fromentel C., Preudhomme C., Fenaux P., Fournier G. Analysis of p53 antibodies in patients with various cancers define B-cell epitopes of human p53: distribution on primary structure and exposure on protein surface. Cancer Res. 1993 Dec 15;53(24):5872–5876. [PubMed] [Google Scholar]
  21. Lubin R., Schlichtholz B., Teillaud J. L., Garay E., Bussel A., Wild C. P. p53 antibodies in patients with various types of cancer: assay, identification, and characterization. Clin Cancer Res. 1995 Dec;1(12):1463–1469. [PubMed] [Google Scholar]
  22. Marks J. R., Davidoff A. M., Kerns B. J., Humphrey P. A., Pence J. C., Dodge R. K., Clarke-Pearson D. L., Iglehart J. D., Bast R. C., Jr, Berchuck A. Overexpression and mutation of p53 in epithelial ovarian cancer. Cancer Res. 1991 Jun 1;51(11):2979–2984. [PubMed] [Google Scholar]
  23. Milner B. J., Allan L. A., Eccles D. M., Kitchener H. C., Leonard R. C., Kelly K. F., Parkin D. E., Haites N. E. p53 mutation is a common genetic event in ovarian carcinoma. Cancer Res. 1993 May 1;53(9):2128–2132. [PubMed] [Google Scholar]
  24. Mudenda B., Green J. A., Green B., Jenkins J. R., Robertson L., Tarunina M., Leinster S. J. The relationship between serum p53 autoantibodies and characteristics of human breast cancer. Br J Cancer. 1994 Jun;69(6):1115–1119. doi: 10.1038/bjc.1994.219. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Nedbal W., Frey M., Willemann B., Zentgraf H., Sczakiel G. Mechanistic insights into p53-promoted RNA-RNA annealing. J Mol Biol. 1997 Mar 7;266(4):677–687. doi: 10.1006/jmbi.1996.0813. [DOI] [PubMed] [Google Scholar]
  26. Peyrat J. P., Bonneterre J., Lubin R., Vanlemmens L., Fournier J., Soussi T. Prognostic significance of circulating P53 antibodies in patients undergoing surgery for locoregional breast cancer. Lancet. 1995 Mar 11;345(8950):621–622. doi: 10.1016/s0140-6736(95)90523-5. [DOI] [PubMed] [Google Scholar]
  27. Rohayem J., Conrad K., Zimmermann T., Frank K. H. Comparison of the diagnostic accuracy of three commercially available enzyme immunoassays for anti-p53 antibodies. Clin Chem. 1999 Nov;45(11):2014–2016. [PubMed] [Google Scholar]
  28. Runnebaum I. B., Kieback D. G., Mobus V. J., Tong X. W., Kreienberg R. Subcellular localization of accumulated p53 in ovarian cancer cells. Gynecol Oncol. 1996 May;61(2):266–271. doi: 10.1006/gyno.1996.0137. [DOI] [PubMed] [Google Scholar]
  29. Schlichtholz B., Legros Y., Gillet D., Gaillard C., Marty M., Lane D., Calvo F., Soussi T. The immune response to p53 in breast cancer patients is directed against immunodominant epitopes unrelated to the mutational hot spot. Cancer Res. 1992 Nov 15;52(22):6380–6384. [PubMed] [Google Scholar]
  30. Schlichtholz B., Trédaniel J., Lubin R., Zalcman G., Hirsch A., Soussi T. Analyses of p53 antibodies in sera of patients with lung carcinoma define immunodominant regions in the p53 protein. Br J Cancer. 1994 May;69(5):809–816. doi: 10.1038/bjc.1994.159. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Soussi T., May P. Structural aspects of the p53 protein in relation to gene evolution: a second look. J Mol Biol. 1996 Aug 2;260(5):623–637. doi: 10.1006/jmbi.1996.0425. [DOI] [PubMed] [Google Scholar]
  32. Vogl F. D., Stickeler E., Weyermann M., Köhler T., Grill H. J., Negri G., Kreienberg R., Runnebaum I. B. p53 autoantibodies in patients with primary ovarian cancer are associated with higher age, advanced stage and a higher proportion of p53-positive tumor cells. Oncology. 1999 Nov;57(4):324–329. doi: 10.1159/000012069. [DOI] [PubMed] [Google Scholar]
  33. Wen W. H., Reles A., Runnebaum I. B., Sullivan-Halley J., Bernstein L., Jones L. A., Felix J. C., Kreienberg R., el-Naggar A., Press M. F. p53 mutations and expression in ovarian cancers: correlation with overall survival. Int J Gynecol Pathol. 1999 Jan;18(1):29–41. doi: 10.1097/00004347-199901000-00005. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES